Abbott Announces Early Results of Tender Offer and Consent Solicitation for CFR International SpA 5.125% Senior Notes due 2022

ABBOTT PARK, Ill., Dec. 30, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) today reported early results for the tender offer and related consent solicitation commenced by its wholly-owned subsidiary, Abbott Laboratories (Chile) Holdco (Dos) SpA, a Chilean corporation ("ALH"), to purchase for cash any or all of the outstanding 5.125% Senior Notes due 2022 (the "Notes") issued by CFR International SpA, a Chilean corporation and subsidiary of ALH. Abbott has been advised that an aggregate of $292,893,000 principal amount of Notes, representing 97.6% of the outstanding Notes, was tendered as of 5 p.m., New York City time, on Dec. 29, 2014. ALH has accepted for payment all Notes that were validly tendered and not subsequently withdrawn.

Under the terms of the tender offer and consent solicitation, holders of tendered Notes consented to certain amendments to the indenture governing the Notes.  Consents from holders of the requisite aggregate principal amount of the outstanding Notes were received, and upon payment for such Notes, the indenture amendments will be effective. Any Notes not tendered and purchased in the tender offer will be subject to the terms of the amended indenture.

The tender offer will expire at 12 p.m., New York City time, on Jan. 14, 2015, unless extended or earlier terminated. 

About Abbott

Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 69,000 people.

Visit Abbott at www.abbott.com and connect with us on Twitter at @AbbottNews.

Private Securities Litigation Reform Act of 1995 – A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2013, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/abbott-announces-early-results-of-tender-offer-and-consent-solicitation-for-cfr-international-spa-5125-senior-notes-due-2022-300014405.html

SOURCE Abbott

Suggested Articles

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.

Eli Lilly and Boehringer's Jardiance fell short in a heart failure trial in patients with or without diabetes—a test AZ's rival Farxiga recently aced.